US-based pharmaceutical major Merck has opened a €100m R&D facility at Ballydine, Co Tipperary, Ireland.

The facility will house 70 new R&D roles, with the capacity to expand to 120 should new innovative medicines be developed. An additional investment of €6m is already planned to cater for the extra capacity.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Six drugs are currently in development at the facility, including Merck’s candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication.

Three of Merck’s five top priority candidate medicine research programmes are now based at the facility.

Ballydine will also supply materials to support Merck’s worldwide clinical research programme.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now